Pages that link to "Q44226962"
Jump to navigation
Jump to search
The following pages link to Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. (Q44226962):
Displaying 50 items.
- Tackling ALK in non-small cell lung cancer: the role of novel inhibitors (Q26740329) (← links)
- Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib (Q28083711) (← links)
- Concomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases. (Q30234436) (← links)
- Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer (Q33648747) (← links)
- Mortality outcomes of low-dose computed tomography screening for lung cancer in urban China: a decision analysis and implications for practice (Q33908633) (← links)
- Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry (Q34231928) (← links)
- Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis (Q35113209) (← links)
- Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 (Q35136424) (← links)
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience (Q35541778) (← links)
- Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma (Q35791225) (← links)
- Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report (Q35916214) (← links)
- KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas (Q35951226) (← links)
- Global efforts in conquering lung cancer in China (Q36121196) (← links)
- Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma (Q36151764) (← links)
- Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations (Q36477762) (← links)
- Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target (Q36863247) (← links)
- Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer (Q36860098) (← links)
- Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases (Q36924440) (← links)
- Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases (Q37042926) (← links)
- Clinical effect of pemetrexed as the first-line treatment in Chinese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (Q37060397) (← links)
- Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis (Q37381391) (← links)
- Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations (Q37662206) (← links)
- Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond (Q38264440) (← links)
- Discovery of a potent dual ALK and EGFR T790M inhibitor (Q38702793) (← links)
- Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC. (Q38846823) (← links)
- Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature (Q39259095) (← links)
- Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations (Q40233288) (← links)
- Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocation (Q40986813) (← links)
- ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma (Q41037400) (← links)
- Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature (Q41162110) (← links)
- A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation (Q41348354) (← links)
- Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis (Q41475904) (← links)
- Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report (Q42360043) (← links)
- Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma (Q46556584) (← links)
- The applications of liquid biopsy in resistance surveillance of anaplastic lymphoma kinase inhibitor (Q47115593) (← links)
- ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases (Q47152298) (← links)
- Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. (Q51034792) (← links)
- Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib: A Case Report. (Q52661848) (← links)
- Concomitant EGFR and KRAS mutations in ALK-rearranged lung cancer. (Q55067795) (← links)
- Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature. (Q55263540) (← links)
- Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib (Q58083092) (← links)
- Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer (Q58565363) (← links)
- (Q58714451) (← links)
- Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression (Q59808389) (← links)
- Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer (Q64092527) (← links)
- Frequency, clinical features and differential response to therapy of concurrent ALK/EGFR alterations in Chinese lung cancer patients. (Q64966333) (← links)
- High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer (Q86214764) (← links)
- The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China (Q89668634) (← links)
- Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line (Q90039016) (← links)
- Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country (Q90160764) (← links)